Savara Inc Share-based Payment Arrangement, Decrease for Tax Withholding Obligation
Savara Inc (SVRA) reported Share-based Payment Arrangement, Decrease for Tax Withholding Obligation of $5.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-08-11
- Savara Inc share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-06-30 was $5.00K, a 95.65% decline year-over-year.
- Savara Inc share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2026-03-31 was $240.00K, a 11.63% increase year-over-year.
- Savara Inc share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-09-30 was $23.00K, a 75.53% decline year-over-year.
- Savara Inc share-based payment arrangement, decrease for tax withholding obligation for the quarter ending 2025-06-30 was $115.00K, a 5650.00% increase year-over-year.
- Savara Inc share-based payment arrangement, decrease for tax withholding obligation for fiscal 2025 was $5.14M, a 416.58% increase from fiscal 2024.
- Savara Inc share-based payment arrangement, decrease for tax withholding obligation for fiscal 2024 was $995.00K, a 17.63% decline from fiscal 2023.
- Savara Inc share-based payment arrangement, decrease for tax withholding obligation for fiscal 2023 was $1.21M, a 40166.67% increase from fiscal 2022.
- Savara Inc share-based payment arrangement, decrease for tax withholding obligation for fiscal 2022 was $3.00K, a 96.15% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 3 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 6 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 9 month | Share-based Payment Arrangement, Decrease for Tax Withholding Obligation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.00K 10-Q · filed 2026-08-11 | $245.00K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $240.00K 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $5.14M 10-K · filed 2026-03-13 | |||
| 2025-09-30 | $23.00K 10-Q · filed 2025-11-12 | $138.00K derived: sum of 2 quarters · filed 2026-08-11 | $353.00K derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $115.00K 10-Q · filed 2026-08-11 | $330.00K derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $215.00K 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $995.00K 10-K · filed 2026-03-13 | |||
| 2024-09-30 | $94.00K 10-Q · filed 2025-11-12 | $96.00K derived: sum of 2 quarters · filed 2025-11-12 | $98.00K derived: sum of 3 quarters · filed 2025-11-12 | |
| 2024-06-30 | $2.00K 10-Q · filed 2025-11-12 | $4.00K derived: sum of 2 quarters · filed 2025-11-12 | ||
| 2024-03-31 | $2.00K 10-Q · filed 2025-11-12 | |||
| 2023-12-31 | $1.21M 10-K · filed 2025-03-27 | |||
| 2023-09-30 | $182.00K 10-Q · filed 2024-11-12 | |||
| 2023-03-31 | $1.00K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $3.00K 10-K · filed 2024-03-07 | |||
| 2022-09-30 | $1.00K 10-Q · filed 2023-11-09 | |||
| 2022-03-31 | $1.00K 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $78.00K 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |